A Case of Lipogranulomatosis Farber: Some Clinical and Ultrastructural Aspects

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 1985 Jan 1

PMID 3987715

Citations 9

Authors

U Burck

H W Moser

H H Goebel

R GRUTTNER

K R Held

Affiliations

Soon will be listed here.

Abstract

A 20-month-old girl showed typical clinical signs of Farber disease: hoarseness since birth, and periarticular subcutaneous painful nodules. Complete deficiency of acid ceramidase activity was found in cultured skin fibroblasts. An electron microscopic examination of a dermal nodule disclosed pathognomonic tubular inclusions in histiocytes. In epidermal cells zebra-body-like and needle-like lysosomal inclusions were found. Their ultrastructure is different from that of the intrahistiocytic lysosomal inclusions. Probably three clinical types of Farber disease may be distinguished according to the symptomatology and the course of the disease: a severe type, an intermediate type and a relatively mild type. The activity of acid ceramidase does not correlate with prognosis of the disease, while a correlation between first appearance of dermal nodules and clinical course appears likely.

Citing Articles

Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases.

Pandey M Biomedicines. 2023; 11(4).

PMID: 37189685 PMC: 10135900. DOI: 10.3390/biomedicines11041067.

Acid ceramidase deficiency: Farber disease and SMA-PME.

Yu F, Amintas S, Levade T, Medin J Orphanet J Rare Dis. 2018; 13(1):121.

PMID: 30029679 PMC: 6053731. DOI: 10.1186/s13023-018-0845-z.

Identification of ASAH1 as a susceptibility gene for familial keloids.

Santos-Cortez R, Hu Y, Sun F, Benahmed-Miniuk F, Tao J, Kanaujiya J Eur J Hum Genet. 2017; 25(10):1155-1161.

PMID: 28905881 PMC: 5602022. DOI: 10.1038/ejhg.2017.121.

Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.

Sikora J, Dworski S, Jones E, Kamani M, Micsenyi M, Sawada T Am J Pathol. 2017; 187(4):864-883.

PMID: 28342444 PMC: 5397689. DOI: 10.1016/j.ajpath.2016.12.005.

Markedly perturbed hematopoiesis in acid ceramidase deficient mice.

Dworski S, Berger A, Furlonger C, Moreau J, Yoshimitsu M, Trentadue J Haematologica. 2015; 100(5):e162-5.

PMID: 25682603 PMC: 4420221. DOI: 10.3324/haematol.2014.108530.

References

Farber S . A lipid metabolic disorder: disseminated lipogranulomatosis; a syndrome with similarity to, and important difference from, Niemann-Pick and Hand-Schüller-Christian disease. AMA Am J Dis Child. 1952; 84(4):499-500. View

Sugita M, DULANEY J, Moser H . Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science. 1972; 178(4065):1100-2. DOI: 10.1126/science.178.4065.1100. View

Battin J, Vital C, Azanza X . [A rare neurolipidosis with subcutaneous and articular node lesions: disseminated Farber's lipogranulomatosis]. Ann Dermatol Syphiligr (Paris). 1970; 97(3):241-8. View

Gray G, White R . Glycosphingolipids and ceramides in human and pig epidermis. J Invest Dermatol. 1978; 70(6):336-41. DOI: 10.1111/1523-1747.ep12543527. View

Vital C, Battin J, Rivel J, Hehunstre J . [Ultrastructural aspects of peripheral nerve lesions in one case of Farber's disease]. Rev Neurol (Paris). 1976; 132(6):419-23. View

Barriere H, Gillot F . [Farber's lipogranulomatosis]. Nouv Presse Med. 1972; 2(12):767-70. View

Pavone L, Moser H, Mollica F, Reitano C, Durand P . Farber's lipogranulomatosis: ceramidase deficiency and prolonged survival in three relatives. Johns Hopkins Med J. 1980; 147(5):193-6. View

DUSTIN P, Tondeur M, Jonniaux G, PELC S . [Farber's disease. Anatomoclinical and ultrastructural study]. Bull Acad R Med Belg. 1974; 13(9):733-62. View

Goebel H, Zeman W, Patel V, Pullarkat R, Lenard H . On the ultrastructural diversity and essence of residual bodies in neuronal ceroid-lipofuscinosis. Mech Ageing Dev. 1979; 10(1-2):53-70. DOI: 10.1016/0047-6374(79)90070-8. View

10.

Toppet M, Jonniaux G, CREMER N, Tondeur M, PELC S . Farber's disease as a ceramidosis: clinical, radiological and biochemical aspects. Acta Paediatr Scand. 1978; 67(1):113-9. DOI: 10.1111/j.1651-2227.1978.tb16287.x. View

11.

Schmoeckel C, Hohlfed M . A specific ultrastructural marker for disseminated lipogranulomatosis (Faber). Arch Dermatol Res. 1979; 266(2):187-96. DOI: 10.1007/BF00694628. View

12.

COGAN D, Kuwabara T, Moser H, HAZARD G . Retinopathy in a case of Farber's lipogranulomatosis. Arch Ophthalmol. 1966; 75(6):752-7. DOI: 10.1001/archopht.1966.00970050754007. View

13.

Fensom A, Benson P, Neville B, Moser H, Moser A, DULANEY J . Prenatal diagnosis of Farber's disease. Lancet. 1979; 2(8150):990-2. DOI: 10.1016/s0140-6736(79)92562-5. View

14.

Amirhakimi G, Haghighi P, GHALAMBOR M, Honari S . Familial lipogranulomatosis (Farber's disease). Clin Genet. 1976; 9(6):625-30. DOI: 10.1111/j.1399-0004.1976.tb01624.x. View

15.

MOLZ G . [Farber's disease. Pathologic anatomical findings]. Virchows Arch A Pathol Pathol Anat. 1968; 344(1):86-99. View

16.

Schonenberg H, Lindenfelser R . [Farber's disease (disseminated lipogranulomatosis) (author's transl)]. Monatsschr Kinderheilkd (1902). 1974; 122(4):153-9. View

17.

Moser H, Prensky A, WOLFE H, ROSMAN N . Farber's lipogranulomatosis. Report of a case and demonstration of an excess of free ceramide and ganglioside. Am J Med. 1969; 47(6):869-90. DOI: 10.1016/0002-9343(69)90202-2. View

18.

Samuelsson K, Zetterstrom R . Ceramides in a patient with lipogranulomatosis (Farber's disease) with chronic course. Scand J Clin Lab Invest. 1971; 27(4):393-405. DOI: 10.3109/00365517109080235. View